PTP4A2

PTP4A2/PRL-2 is a prenylated protein tyrosine phosphatase that drives cell proliferation, migration, and oncogenesis across hematopoietic, endothelial, and epithelial lineages (PMID:20841483, PMID:24753135). Its C-terminal CAAX motif directs farnesylation (PMID:9514946) and early-endosome localization, and the prenylated protein engages the beta-subunit of Rab geranylgeranyltransferase II (PMID:11447212). Both catalytic activity and C-terminal prenylation are required for PRL-2 to drive ERK phosphorylation and nuclear translocation, acting through an ERK-dependent, Src-independent p130Cas pathway to promote migration and invasion (PMID:21765462). PRL-2 forms a functional heterodimer with the magnesium transporter CNNM3, with an Asp residue in the CNNM3 Bateman/CBS-domain loop inserting into the PRL-2 catalytic cavity; this non-catalytic interaction regulates intracellular magnesium and confers an oncogenic growth advantage, and disrupting the interface impairs CNNM3 channel activity and breast cancer proliferation (PMID:24632616, PMID:26969161). PRL-2 also acts as a catalytic phosphatase on defined substrates: it dephosphorylates VCP/p97 at Tyr805 to enable assembly of the ELDR cofactor complex (UBXN6/UBXD1, PLAA) and drive lysophagy (PMID:36300783), and it dephosphorylates p53 at Ser392 to destabilize p53 and sustain leukemia-initiating cells (PMID:41985006). In stem and vascular compartments PRL-2 mediates SCF/KIT-driven AKT and ERK activation for hematopoietic stem cell self-renewal (PMID:24753135) and VEGF-A/DLL-4/NOTCH-1 signaling for sprouting angiogenesis (PMID:33097786).

1. 1998 Medium

   Establishing that PRL-2 carries a C-terminal CAAX prenylation motif defined it as a membrane-targeted phosphatase rather than a soluble enzyme, framing all later localization and function studies.

   Evidence Sequence analysis identifying a conserved prenylation motif placing PRL-2 with PRL-1 and Cdc14p/PTEN

   PMID:9514946

   Open questions at the time

   • Prenylation inferred from motif, not yet biochemically demonstrated in this study
   • No functional consequence of prenylation established
2. 2001 High

   Demonstrating that farnesylated PRL-2 binds betaGGT II and localizes to early endosomes provided the first physical partner and subcellular address, linking prenylation to a defined location.

   Evidence Yeast two-hybrid, Co-IP in HeLa cells, chimeric domain mapping, isoprenoid analysis, and GGT II activity assay

   PMID:11447212

   Open questions at the time

   • Functional role of betaGGT II binding for downstream signaling unresolved
   • Whether endosomal localization is required for catalytic substrate access not tested
3. 2010 High

   Gain- and loss-of-function studies showed PRL-2 promotes migration, cytokine-driven growth, and ERK1/2-dependent tumor formation, establishing it as a pro-oncogenic phosphatase in vivo.

   Evidence Overexpression in hematopoietic cells and breast cancer lines, siRNA knockdown, xenograft and transgenic mouse models with ERK1/2 readout

   PMID:20226699 PMID:20841483

   Open questions at the time

   • Direct phosphatase substrates not identified
   • Mechanism linking PRL-2 to ERK activation undefined
4. 2011 High

   Showing that both catalytic activity and prenylation are required for ERK phosphorylation, nuclear translocation, and the p130Cas migration pathway connected PRL-2's two structural features to its pro-invasive output.

   Evidence siRNA knockdown with resistant rescue, C101S catalytic-dead and CAAX-deletion mutants, pathway Western blots, migration/invasion assays

   PMID:21765462

   Open questions at the time

   • Direct dephosphorylation target upstream of ERK/p130Cas not identified
   • How prenylation contributes mechanistically beyond localization unclear
5. 2014 High

   Identifying the PRL-2·CNNM3 heterodimer and the Ptp4a2-null magnesium phenotype revealed a non-catalytic, interaction-based mechanism for regulating cellular magnesium and oncogenic growth.

   Evidence Endogenous reciprocal Co-IP, magnesium influx measurement, Ptp4a2 knockout mouse serum magnesium, xenograft with CNNM3 binding mutant

   PMID:24632616

   Open questions at the time

   • CNNM3 is not a phosphorylated substrate, leaving the molecular basis of magnesium regulation incomplete
   • Link between magnesium handling and growth advantage not mechanistically dissected
6. 2014 High

   Conditional knockout established a physiological requirement for PTP4A2 phosphatase activity in HSC self-renewal via SCF/KIT-driven AKT and ERK signaling.

   Evidence Serial bone marrow transplantation in Ptp4a2 KO mice, phosphatase-dead rescue, SCF stimulation, oncogenic KIT epistasis

   PMID:24753135

   Open questions at the time

   • Direct substrate within the SCF/KIT-AKT/ERK axis not identified
   • Whether the same mechanism operates outside hematopoiesis untested here
7. 2016 High

   Mapping the CNNM3 Asp-426 residue into the PRL-2 catalytic cavity and showing a PRL inhibitor disrupts the complex defined a druggable interface controlling CNNM3 channel activity and tumor proliferation.

   Evidence D426A mutagenesis, whole-cell voltage clamping, molecular modeling, orthotopic xenograft, Co-IP, inhibitor proliferation assays

   PMID:26969161

   Open questions at the time

   • How catalytic-pocket occupancy by CNNM3 relates to PRL-2 phosphatase activity on other substrates unresolved
   • In vivo selectivity of the PRL inhibitor not addressed
8. 2020 High

   Endothelial-specific knockout demonstrated PTP4A2 is required for sprouting angiogenesis and arteriovenous differentiation through VEGF-A and DLL-4/NOTCH-1 signaling, extending its role to vascular development.

   Evidence Inducible endothelial-specific and global Ptp4a2 KO mice, retinal vascular outgrowth analysis, migration assays, VEGF-A/NOTCH-1 readouts

   PMID:33097786

   Open questions at the time

   • Direct substrate in the VEGF-A/NOTCH axis not identified
   • Whether ERK-dependent migration mechanism from epithelial cells applies in endothelium not confirmed
9. 2022 High

   Unbiased substrate trapping identified VCP/p97 Tyr805 as a direct PTP4A2 substrate, linking the phosphatase to ELDR complex assembly and lysophagy with an in vivo kidney-injury phenotype.

   Evidence Substrate trapping with mass spectrometry, biochemical dephosphorylation assay, Co-IP of VCP cofactors, Ptp4a2 KO MEFs and mice, acute kidney injury model

   PMID:36300783

   Open questions at the time

   • How VCP dephosphorylation is spatially coordinated with endosomal/lysosomal localization not detailed
   • Relationship between lysophagy role and oncogenic functions unexplored
10. 2026 High

    Identifying p53 Ser392 as a PTP4A2 dephosphorylation target showed how the phosphatase destabilizes p53 to sustain leukemia-initiating cells, providing a direct oncogenic substrate.

    Evidence Reciprocal Co-IP, Ser392 dephosphorylation assay, Ptp4a2 KO in LICs, KMT2A-MLLT3 AML mouse survival model, apoptosis/senescence assays

    PMID:41985006

    Open questions at the time

    • Structural basis of PTP4A2-p53 recognition not defined
    • Whether p53 regulation operates in non-leukemic PTP4A2 contexts untested

• How PTP4A2 selects among its diverse substrates (VCP, p53) and non-catalytic partners (CNNM3) in different cellular contexts, and how prenylation/endosomal localization gates these activities, remains unresolved.
• No unifying model for substrate selection across tissues
• Direct substrates underlying ERK/AKT activation in stem and endothelial cells still unidentified
• Structural integration of catalytic vs. CNNM3-binding modes not established